Mulligan SNAG Technique in Individuals With Lumbar Intervertebral Disc Protrusion

April 3, 2025 updated by: Ugur Cavlak, Biruni University

Effect of the Mulligan SNAG Technique on Structure of Intervertebral Disc and Physical Functioning in Individuals With Lumbar Intervertebral Disc Protrusion: A Randomized Controlled Study

This study aimed to examine the effects of the Mulligan SNAG mobilization technique, applied in addition to conventional physiotherapy on the structure of the intervertebral disc and physical functioning in patients diagnosed with low back pain due to lumbar intervertebral disc protrusion. 38 volunteer patients will participate in the study. The participants will be randomized as an interventional and control gropus.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Participants will be treated 3 days a week for 4 weeks. The session duration will be 40-45 minutes. Visual analog scale-VAS, oswestry disability index, magnetic imaging-MRI assessment, functıonal independence scale-FIM, Tampa kinesiophobia scale, one leg stand test, sit-stand test, 10-meter walking test, cadence , Nottingham health profile will be used to assses the participants in the two groups. All participants will be evaluated in the 5th week of the study. The program includes physical therapy session (Hot packed, trans cuteneal electric stimulation, therapeutic ultrasound, and therapautic exercises) and the Mulligan SNAG mobilization technique.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
38

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Turkey
    • Zeytinburnu
      • İ̇stanbul, Zeytinburnu, Turkey, 34010
        • Faculty of Health Sciences in Biruni University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Being between the ages of 20-60
  2. Those diagnosed with lumbar intervertebral disc heniation (protrusion on L1-L2, L2-L3, L3-L4, L4-L5, L5-S1) at a single level
  3. Those who voluntarily agreed to participate in the study

Exclusion Criteria:

  • Individuals diagnosed with Lumbar Bulging, Extruded, Sequestered discs
  • Individuals who have undergone lumbar region spinal surgery
  • Individuals with spinal deformity (scoliosis, spondylolisthesis, Ankylosing Spondylitis)
  • Individuals with lumbar stenosis
  • Pregnant women
  • Individuals receiving treatment for malignancy (primary or metastatic tumoral conditions in the lumbar region)
  • Individuals diagnosed with advanced osteoporosis
  • Individuals diagnosed with discitis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Group 1
SNAG
Other: Mulligan SNAG mobilization tecnique
Mulligan SNAG mobilization tecnique
Other: Conventional Physiotherapy
Conventional Physiotherapy
Active Comparator: Group 2
Physiotherapy
Other: Conventional Physiotherapy
Conventional Physiotherapy

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Magnetic Resonance Imaging
Time Frame: baseline and iafter the intervention (in the 5th week)
to measure protrusion (bigger amount means worse outcome)
baseline and iafter the intervention (in the 5th week)
Visual Analog Scale-VAS
Time Frame: baseline and immediately after the intervention (in the 5th week)
to measure pain intensity (min. score is 0 and max. score is 10- higher score means worse outcome)
baseline and immediately after the intervention (in the 5th week)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Oswestry Disability Index-ODI
Time Frame: baseline and immediately after the intervention (in the 5th week)
to describe disabilty level resulting from pain (min. score is 0 and max. score is 50- higher score means worse outcome)
baseline and immediately after the intervention (in the 5th week)
Functional Independence Measure- FIM
Time Frame: baseline and immediately after the intervention (in the 5th week)
to measure independency in daily living activities (min. score is 18 and max score is 156- higger score means better independency in daily living activities)
baseline and immediately after the intervention (in the 5th week)
Tampa Kinesiophobia Scale- TKS
Time Frame: baseline and immediately after the intervention (in the 5th week)
to measure anxiety-avoidance state (min. score is 17 and max. score is 68- higher score means worse outcome)
baseline and immediately after the intervention (in the 5th week)
One Leg stand Test- OLST
Time Frame: before and after the intervention (in the 5th week)
to measure static balance ability (min. score 0 and max. score is 60- Higher score means better balance)
before and after the intervention (in the 5th week)
Sit-Stand Test-SST
Time Frame: before and after the intervention (in the 5th week)
to measure lower extremity performance (min. score is 0 and max. score is 30- higher score means better outcome)
before and after the intervention (in the 5th week)
10-m Walking test and cadance measurement
Time Frame: before and after the intervention (in the 5th week)
to measure walking speed (in second- higher score means worse outcome) and cadance (number of steps during the test- higher score means better outcome)
before and after the intervention (in the 5th week)
Nottingham Health profile-NHP
Time Frame: before and after the intervention (in the 5th week)
to describe level of quality of life (min. score is 38 and max. score is 3800 - higher score means poor health)
before and after the intervention (in the 5th week)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Biruni University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: UGUR CAVLAK, Prof., Biruni University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
February 16, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 30, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 15, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 16, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 24, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 25, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 6, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 3, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BiruniUniversity34

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings